関連する実験動画
Updated: Aug 2, 2026

07:29
Programmed Electrical Stimulation in Mice
Published on: May 26, 2010
まとめ
静脈内投与のディソピラミドは,AVブロックの患者において,心房静脈 (AV) の結節伝導を悪化させなかった. しかし,逆行性AV伝導を抑制し,心室内閉塞に影響を与えました.
科学分野:
- 心臓病学 心臓病学
- 電気生理学 電気生理学
背景:
- 心房静脈 (AV) ブロックは,心臓の電気伝導に影響を与える状態です.
- ディソピラミドは,心臓伝導に潜在的な影響を及ぼす抗不律薬である.
研究 の 目的:
- 1級またはモビッツI AVブロックの患者における静脈内ジソピラミドの電気生理学的効果を評価する.
- ディソピラミドの安全性とAV節関節機能と逆行伝導に対する影響を評価する.
主な方法:
- 電子生理学的薬物検査は,IV ディソピラミド投与前のおよび後の17人の患者に実施されました.
- シヌスノード回復時間,耐火期,伝導時間などの主要な電気生理学的パラメータが測定されました.
主要な成果:
- ディソピラミドは,シヌス節機能,心房屈折性,またはAV節伝導時間に大きな変化を起こさなかった.
- AVノダルの有効耐火期の有意な減少が観察されました.
- 静脈管内伝導時間と心室内閉塞のサイクル長さは著しく増加しました.
結論:
- 静脈内投与ディソピラミドは,治療レベルでは,AV結節機能不全の患者でAV結節伝導に有害な影響を示さなかった.
- ディソピラミドは逆行性心房伝導を抑制することが判明しました.
関連する概念動画
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

